FDA expands tirzepatide label to include cardiovascular risk reduction
The indication broadens use in type 2 diabetes, giving prescribers a labeled cardiovascular claim alongside glycemic and weight effects.
DO
By Daniel Okafor · Regulatory Correspondent
Aug 28 03:00 ETSource: Patient Care Online
The wire
- 01The FDA has expanded the tirzepatide label to cover cardiovascular risk reduction in patients with type 2 diabetes.
- 02A labeled cardiovascular indication changes formulary arguments and prescribing rationale for clinicians choosing between incretin agents.
- 03Details of the supporting outcomes data and any restrictions in the revised label should be checked against the full prescribing information.
From the source
Read at patientcareonline.comFDA Expands Tirzepatide Label for Cardiovascular Risk Reduction in Type 2 Diabetes